|
|
||||||||||||||
|
|
|||||||||||||||
MOTILITY AND VISCERAL SENSATION |
1 Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany
2 Department of Gastroenterology, Ludwig-Maximilians University, Munich, Germany
Correspondence to:
Correspondence to:
Professor M Katschinski, Department of Gastroenterology, Baldingerstr, 35033 Marburg, Germany;
katschin{at}post.med.uni-marburg.de
ABSTRACT
Background: Glucagon-like peptide-1(736)amide (GLP-1) retards gastric emptying, reduces food intake, and inhibits antroduodenal and stimulates pyloric motility.
Aims: To assess the effects of synthetic GLP-1 on fundus tone and volume waves, gastric compliance, and perception of gastric distension.
Subjects: Eleven healthy male volunteers.
Methods: Background infusions were saline, or GLP-1 at 0.3 or 0.9 pmol/ kg/min on separate days in random order. Interdigestive fundus motility was recorded by barostat (maximum capacity of intragastric bag 1200 ml) during basal and peptide periods of 60 minutes each. Thereafter stepwise isobaric distensions were performed with ongoing peptide infusion, and gastric sensation was scored.
Results: Low and high loads of GLP-1 induced physiological and supraphysiological plasma immunoreactivities, respectively. GLP-1 dose dependently diminished fundus tone (162.9 (15.0) and 259.5 (17.2) v 121.1 (6.0) ml with saline; p<0.0001). It greatly reduced volume waves and total volume displaced by these events (p<0.0001). Gastric compliance derived from isobaric distension rose in a dose related manner (42.6 (5.5) and 63.6 (7.7) v 27.0 (3.5) ml/mm Hg; p=0.0004) with a concomitant reduction of the pressure at half maximum bag volume (6.4 (0.4) and 5.5 (0.4) v 7.2 (0.1) mm Hg; p<0.0001). GLP-1 did not change perception of isobaric distension but reduced the perception score related to corresponding bag volume (p<0.0001).
Conclusions: GLP-1 is a candidate physiological inhibitory regulator of fundus motility. It allows the stomach to afford a larger volume without increase in sensation.
Keywords: barostat; gastric compliance; gastric tone; isobaric distension; volume waves
Abbreviations: CCK, cholecystokinin; GLP-1, glucagon-like peptide-1(7-36)amide; IR, immunoreactive; MDP, minimal distending pressure; PP, pancreatic polypeptide
This article has been cited by other articles:
![]() |
A. Vella, G. Bock, P. D. Giesler, D. B. Burton, D. B. Serra, M. L. Saylan, B. E. Dunning, J. E. Foley, R. A. Rizza, and M. Camilleri Effects of Dipeptidyl Peptidase-4 Inhibition on Gastrointestinal Function, Meal Appearance, and Glucose Metabolism in Type 2 Diabetes Diabetes, May 1, 2007; 56(5): 1475 - 1480. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Raun, P. von Voss, C. F. Gotfredsen, V. Golozoubova, B. Rolin, and L. B. Knudsen Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not Diabetes, January 1, 2007; 56(1): 8 - 15. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Little, A. N. Pilichiewicz, A. Russo, L. Phillips, K. L. Jones, M. A. Nauck, J. Wishart, M. Horowitz, and C. Feinle-Bisset Effects of Intravenous Glucagon-Like Peptide-1 on Gastric Emptying and Intragastric Distribution in Healthy Subjects: Relationships with Postprandial Glycemic and Insulinemic Responses J. Clin. Endocrinol. Metab., May 1, 2006; 91(5): 1916 - 1923. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Schirra, M Nicolaus, R Roggel, M Katschinski, M Storr, H J Woerle, and B Goke Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans Gut, February 1, 2006; 55(2): 243 - 251. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. K. Chelikani, A. C. Haver, and R. D. Reidelberger Intravenous infusion of glucagon-like peptide-1 potently inhibits food intake, sham feeding, and gastric emptying in rats Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1695 - R1706. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. A. D'Alessio and T. P. Vahl Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890. [Abstract] [Full Text] [PDF] |
||||
![]() |
B D J van den Elzen, R J Bennink, R E Wieringa, G N J Tytgat, and G E E Boeckxstaens Fundic accommodation assessed by SPECT scanning: comparison with the gastric barostat Gut, November 1, 2003; 52(11): 1548 - 1554. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |